SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q2 FY21 results · Jul–Sep 2020
SMS Pharmaceuticals reported revenue from operations of ₹130.13 crore (up 10.4% from Q2 FY20) and net profit of ₹11.23 crore (up 17.6% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 130.13 | 117.90 | +10.4% | 112.90 | +15.3% |
| Other income | 0.92 | 0.58 | +57.6% | 0.81 | +12.8% |
| Total income | 131.04 | 118.48 | +10.6% | 113.71 | +15.2% |
| Profit before tax | 16.25 | 14.42 | +12.7% | 13.81 | +17.7% |
| Net profit for the period | 11.23 | 9.55 | +17.6% | 7.03 | +59.8% |
| EPS, basic (₹) | 1.33 | 1.17 | +13.7% | 0.83 | +60.2% |
| Net margin (%) | 8.6 | 8.1 | 6.2 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 130.13 | 117.90 | +10.4% | 112.90 | +15.3% |
| Other income | 0.92 | 0.58 | +57.6% | 0.81 | +12.8% |
| Total income | 131.04 | 118.48 | +10.6% | 113.71 | +15.2% |
| Profit before tax | 16.25 | 14.42 | +12.7% | 13.81 | +17.7% |
| Net profit for the period | 11.23 | 9.55 | +17.6% | 9.20 | +22.0% |
| EPS, basic (₹) | 1.33 | 1.13 | +17.7% | 1.09 | +22.0% |
| Net margin (%) | 8.6 | 8.1 | 8.2 |
Consolidated
- Filed with BSE
- 09 Nov 2020, 10:10 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2020, 10:10 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE